Prolynx, an Emeryville-based biotechnology company developing ultra-long-acting treatments for obesity and metabolic disorders, has appointed Amer Mirza, PhD, as Chief Scientific Officer, the company announced in July 2026. The appointment comes as Prolynx accelerates advancement of its proprietary portfolio of extended-duration medicines designed for monthly and quarterly dosing, moving programs toward regulatory filings and clinical proof-of-concept. Slone Partners, a nationwide life sciences executive search firm, facilitated the placement.
The hiring marks a critical reinforcement of Prolynx's scientific leadership at a pivotal moment in the company's development. Mirza joins as Prolynx simultaneously announced the appointment of Simon Harnest as Chief Financial Officer, signaling the company's transition from early research to late-stage development. The dual appointments are intended to strengthen the executive bench as Prolynx moves multiple candidates through IND-enabling studies, the regulatory precursor to human trials. Leslie Loveless, CEO and Managing Partner at Slone Partners, characterized Mirza as uniquely suited to translate "groundbreaking science into meaningful clinical progress."
Mirza brings approximately 25 years of drug discovery and development experience across small and large biopharmaceutical organizations. He most recently served as Vice President of Disease Biology and Translational Sciences at Septerna, a GPCR-focused biotech company where he oversaw translational strategy and therapeutic advancement. His career spans metabolic disease, oncology, immunology, and endocrine indications. Previously, he held senior R&D leadership roles at Ascendis Pharma as Vice President of Biomarker Discovery and Development, at Gilead Sciences as Head of Inflammation Biomarkers, and at XOMA as Head of Disease Biology and Translational Medicine. Across his tenure, Mirza has supported advancement of more than two dozen therapeutic programs, including filing over 12 Investigational New Drug applications and four New Drug Applications or Biologics License Applications. He holds a Bachelor of Science in Microbiology and Immunology from the University of Toronto, along with Master of Science and PhD degrees in Hematology and Oncology from the same institution.
Prolynx operates at the intersection of venture capital interest and a competitive obesity market. Founded by Daniel Santi and Gary Ashley, the company leverages proprietary half-life extension chemistry originally developed for oncology to create controlled-release formulations. In December 2025, the company closed a $70 million Series A funding round led by 5AM Ventures and OrbiMed, alongside Monograph Capital, valuing its technology platform as having potential to reshape obesity treatment. Prolynx's lead candidate, PLX-821, is a semaglutide variant designed for once-monthly administration, positioning the company to compete against weekly-dosed therapies from Novo Nordisk and Eli Lilly that dominate current treatment landscapes. The company employed the same linker technology platform for its incretin and non-incretin pipeline, aiming to address tolerability and adherence challenges that persist despite the commercial success of existing GLP-1 receptor agonists.
Mirza's appointment reflects deliberate hiring to address execution risk at a critical juncture. While Prolynx's technology platform has attracted high-profile venture backing and demonstrated clinical credibility by adapting proven oncology chemistry, advancing a competitive obesity portfolio toward regulatory milestones requires experienced translational leadership and disciplined IND-enabling study execution. Mirza's track record in moving programs from early research through regulatory filings suggests the company is prioritizing scientific rigor over speed, a signal that investors and stakeholders may interpret as a focus on de-risking clinical advancement. The appointment occurs as venture capital continues flowing into metabolic disease therapeutics, with annual venture investments exceeding $1 billion in recent years, intensifying competition for experienced scientific leadership across obesity and related disease spaces.
